12:00 AM
Mar 31, 2008
 |  BioCentury  |  Product Development

Moving upstream in psoriasis

While phosphodiesterase-4 inhibition has never lived up to its theoretical potential in asthma or chronic obstructive pulmonary disease, Anacor Pharmaceuticals Inc. believes the mechanism - which works upstream of tumor necrosis factor - will prove particularly useful for psoriasis while avoiding the safety problems associated with the systemically administered anti-TNF biologics.

Inhibiting pro-inflammatory cyto-kines has already proven to be an effective approach in psoriasis, as a number of TNF antagonists are approved to treat moderate to severe forms of the disease. These include Enbrel etanercept from Amgen Inc. and Wyeth, Humira adalimumab from Abbott Laboratories and Remicade infliximab from Johnson & Johnson and Schering-Plough Corp.

However, the TNF antagonists are all injectable biologics. They...

Read the full 606 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >